Stock Research for ARTH


Featured Broker: Ally Invest

Get the due diligence for another stock.


ARTH Stock Chart & Research Data

The ARTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ARTH Due diligence Resources & Stock Charts

The ARTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ARTH Detailed Price Forecast - CNN Money CNN View ARTH Detailed Summary - Google Finance
Yahoo View ARTH Detailed Summary - Yahoo! Finance Zacks View ARTH Stock Research & Analysis -

Stock Analysis

TradeIdeas View ARTH Trends & Analysis - Trade-Ideas Barrons View ARTH Major Holders - Barrons
NASDAQ View ARTH Call Transcripts - NASDAQ Seeking View ARTH Breaking News & Analysis - Seeking Alpha
Spotlight View ARTH Annual Report - OTC Report View ARTH OTC Short Report -
TradeKing View ARTH Fundamentals - TradeKing Charts View ARTH SEC Filings - Bar Chart
WSJ View Historical Prices for ARTH - The WSJ Morningstar View Performance/Total Return for ARTH - Morningstar
MarketWatch View the Analyst Estimates for ARTH - MarketWatch CNBC View the Earnings History for ARTH - CNBC
StockMarketWatch View the ARTH Earnings - StockMarketWatch MacroAxis View ARTH Buy or Sell Recommendations - MacroAxis
Bullish View the ARTH Bullish Patterns - American Bulls Short Pains View ARTH Short Pain Metrics -

Social Media Mentions

StockTwits View ARTH Stock Mentions - StockTwits PennyStocks View ARTH Stock Mentions - PennyStockTweets
Twitter View ARTH Stock Mentions - Twitter Invest Hub View ARTH Investment Forum News - Investor Hub
Yahoo View ARTH Stock Mentions - Yahoo! Message Board Seeking Alpha View ARTH Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ARTH - Insider Cow View Insider Transactions for ARTH - Insider Cow
CNBC View ARTH Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ARTH - OTC Markets
Yahoo View Insider Transactions for ARTH - Yahoo! Finance NASDAQ View Institutional Holdings for ARTH - NASDAQ

Stock Charts

FinViz View ARTH Stock Insight & Charts - StockCharts View ARTH Investment Charts -
BarChart View ARTH Stock Overview & Charts - BarChart Trading View View ARTH User Generated Charts - Trading View

Latest Financial News for ARTH

Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5
Posted on Wednesday September 05, 2018

Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today announced topline data for its irritation/sensitization patch test study of AC5™ Topical Gel (AC5)1. The study was designed to address a request by the Food and Drug Administration (FDA or “the Agency”). The objective of this Study (“Cumulative Irritancy Assay with Delayed Challenge for Allergic Contact Dermatitis Potential of AC5™ Topical Gel (AC5) in Healthy Volunteers”) was to assess irritation and sensitization potential (development of allergic contact dermatitis) of AC5 after repeat applications and then a delayed challenge application of the product to the skin.

Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018
Posted on Tuesday August 28, 2018

FRAMINGHAM, Mass., Aug. 28, 2018-- Arch Therapeutics, Inc., developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the H.C. Wainwright 20 ...

Arch Therapeutics Announces Poster Presentation at the 2018 Military Health System Research Symposium on Tuesday, August 21, 2018
Posted on Thursday August 16, 2018

FRAMINGHAM, Mass., Aug. 16, 2018-- Arch Therapeutics, Inc., developer of AC5™ Topical Gel, today announced that new research involving AC5™ will be presented in a poster at the 2018 Military Health System ...

Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors
Posted on Friday July 20, 2018

Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™ (“AC5™”), today announced the appointment of Punit Dhillon, former President & CEO of OncoSec Medical, Inc. (ONCS), to its Board of Directors (the “Board”) as an independent member effective as of July 19, 2018. Mr. Dhillon brings over 15 years of global industry experience to Arch’s Board with a wealth of knowledge and experience operationally in medical devices, advancing programs from scientific research through clinical development, regulatory approval, and into healthcare systems globally. Mr. Dhillon is experienced and skilled in capital markets and in establishing strategic partnerships, including early and late stage deals with Merck and Pfizer.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.